Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

PLA1A Inhibition Enhances Chemoimmunotherapy Efficacy by Blocking Immunosuppressive Macrophage Polarization in Colorectal Cancer.

Created on 06 Oct 2026

Authors

Ting-Ting Wang, Wei-Shuai Kong, Jia-Jun Li, Ying-Yu Qiu, Ren-Ze Huang, Hao-Jie Chen, Xiao-Tong Duan, Ping Chen, Yi-Chen Xie, Hai-Yu Mo, Yang Xuan, Yi Han, Kun Liao, Zhao-Lei Zeng, Feng-Hua Wang, Yu-Hong Li, Qiang Gao, Huai-Qiang Ju

Published in

Cancer research. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Clinical outcomes are often suboptimal in colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy (NAC). A key determinant of the response to NAC is the functional state of tumor-infiltrating immune cells. Understanding how NAC reshapes the immunological landscape will be essential for refining patient stratification and identifying effective combination treatment strategies. Here, we analyzed paired samples before and after NAC treatment by single-cell RNA sequencing, revealing that NAC treatment significantly reshaped the immune microenvironment. Tumors from NAC non-responders featured increased immunosuppressive M2-like macrophage infiltration, which correlated with elevated phosphatidylserine-specific phospholipase A1 (PLA1A). Mechanistically, PLA1A hydrolyzed phosphatidylserine (PS) exposed by chemotherapy to elevate lysophosphatidylserine (LysoPS), which activated the P2ry10 receptor and downstream signaling to promote M2-like macrophage polarization. Importantly, pharmacological inhibition of PLA1A by cilengitide synergized with chemoimmunotherapy to suppress tumor progression in murine models. Clinically, high plasma PLA1A levels negatively correlated with responses to chemoimmunotherapy. Collectively, these findings reveal a chemotherapy-driven metabolic axis that induces an immunosuppressive milieu by increasing lysoPS release. This axis highlights PLA1A as a therapeutic target to mitigate immunosuppression and improve chemoimmunotherapy efficacy.

PMID:
42832699
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement